Exosomes help deliver drug into the heart of the tumor

Regulators and manufacturers are readying for the opening of the US market, but legal wrangles continue to block the way.

But can pharma manufacturers do more to help prevent medication errors?

What impact will genetic changes have on new medicines currently in development?

It’s the timeless story: Teva wants Mylan, Mylan wants Perrigo, and Perrigo wants none of it

By eliminating protein A, researchers aim to deliver continuous processing at a fraction of the cost of conventional techniques.

We speak to Professor Begoña Calvo to find out more about her research into pharmaco vigilance for biosimilars.

The first US biosimilar has been pocketed and the game is on. We bring six experts to the table to discuss the impact on industry dynamics.

$100 million pledged to kick start investment in new research

FDA scolds company for revealing interim trial results